-
91.发明公开세포투과성을 갖는 Ｒ12 - Ｇｒｉｍ19 융합 펩타이드 및 이를 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물 审中-实审R12-GRIM19具有用于预防或治疗免疫疾病的细胞渗透和包含其的药物组合物的融合肽
公开(公告)号：KR1020130090054A
公开(公告)日：2013-08-13
申请号：KR1020120011092
申请日：2012-02-03
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/4747 , A61K38/1761 , A61K47/64 , C07K7/08 , C07K2319/03
Abstract: PURPOSE: R12-Grim19 fusion peptide is provided to be usefully used as an immune suppressant or a pharmaceutical composition which prevents or treats immune disease including autoimmune disease due to the modulation of an immune reaction, inflammation disease and transplantation rejection disease. CONSTITUTION: Recombinant peptide in which twelve successive arginene (R) and Grim19 are fused is provided. The recombinant peptide has an amino acid sequence represented by a sequence number 1. A vector includes a base sequence coding the peptide. The base sequence comprises a base sequence represented by a sequence number 2. A composition for prevention or treatment of the immune disease includes the peptide.
Abstract translation: 目的：提供R12-Grim19融合肽有效地用作免疫抑制剂或由于免疫反应，炎症疾病和移植排斥疾病的调节而预防或治疗包括自身免疫疾病在内的免疫疾病的药物组合物。 构成：提供其中十二个连续的精氨酸（R）和Grim19融合的重组肽。 重组肽具有由序列号1表示的氨基酸序列。载体包括编码该肽的碱基序列。 碱基序列包含由序列号2表示的碱基序列。用于预防或治疗免疫疾病的组合物包括该肽。
-
公开(公告)号：KR1020120129120A
公开(公告)日：2012-11-28
申请号：KR1020110047180
申请日：2011-05-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/203 , A61K9/127 , A61P29/00 , A61P37/00
Abstract: PURPOSE: An immunotherapeutic agent of a nanosome form containing retinoic acid is provided to ensure high retinoic acid transfer rate to a target site and to effectively suppress TNF-alpha and IL-17 generation. CONSTITUTION: An immunotherapeutic agent of a nanosome form contains a cell suspension and retinoic acid. The cell suspension is a cell membrane in eukaryotic cell lysate. The immune diseases are autoimmune diseases, inflammatory diseases, and cell, tissue, or organ transplantation rejection. A method for manufacturing the immunotherapeutic agent comprises: a step of suspending eukaryotic cells; a step of passing the suspension solution through a membrane filter; a step of adding retinoic acid to the solution; and a step of isolating immunotherapeutic agent of a nanosome from the solution. [Reference numerals] (AA) RA-containing nanosome
Abstract translation: 目的：提供含有视黄酸的纳米体形式的免疫治疗剂，以确保目标部位的高视黄酸转移率，有效抑制TNF-α和IL-17的产生。 构成：纳米体形式的免疫治疗剂含有细胞悬浮液和视黄酸。 细胞悬浮液是真核细胞裂解物中的细胞膜。 免疫疾病是自身免疫疾病，炎性疾病，细胞，组织或器官移植排斥。 制备免疫治疗剂的方法包括：使真核细胞悬浮的步骤; 使悬浮液通过膜过滤器的步骤; 向溶液中加入视黄酸的步骤; 以及从溶液中分离纳米体的免疫治疗剂的步骤。 （AA）RA的纳米体
-
公开(公告)号：KR101187195B1
公开(公告)日：2012-10-02
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 위장관 궤양(gastrointestinal ulcer)의 예방 또는 치료용 약학 조성물을 제공한다.-
公开(公告)号：KR1020120095046A
公开(公告)日：2012-08-28
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/20 , A61K48/005 , Y10S424/81
Abstract: PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Abstract translation: 目的：提供一种用于预防或治疗免疫排斥疾病（包括IL-27）的组合物，用于通过在移植的细胞或器官移植后抑制对宿主的排斥来减轻免疫排斥疾病。 构成：用于预防或治疗免疫排斥疾病的组合物包括IL-27作为活性成分。 IL-27具有序列号1（SEQ ID NO：1）中描述的氨基酸序列。 用于预防或治疗免疫排斥疾病的组合物包括编码IL-27作为活性成分的含有多核苷酸的载体。 多核苷酸具有序列号2中描述的碱基序列。免疫排斥疾病是移植物抗宿主病。
-
公开(公告)号：KR101144563B1
公开(公告)日：2012-05-11
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
-
Patent Agency Ranking
公开(公告)号：KR1020120021239A
公开(公告)日：2012-03-08
申请号：KR1020110086459
申请日：2011-08-29
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P35/00
CPC classification number: A61K31/4704
Abstract: PURPOSE: A composition containing rebamipide for preventing or treating cancer or immune diseases is provided to suppress Th17 cell differentiation and to enhance immune regulatory T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune diseases contains rebamipid compounds or pharmaceutically acceptable salt thereof as an active ingredient. The immune diseases include autoimmune disease, inflammatory disease, and transplantation rejection. A method for reducing or suppressing differentiation of immature T cells into Th17 cell in vitro comprises a step of treating rebamipid compounds or pharmaceutically acceptable salt thereof.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的瑞巴派特的组合物以抑制Th17细胞分化并增强免疫调节性T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有雷米帕派化合物或其药学上可接受的盐作为活性成分。 免疫疾病包括自身免疫性疾病，炎性疾病和移植排斥反应。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括处理rebamipid化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
公开(公告)号：KR1020110125495A
公开(公告)日：2011-11-21
申请号：KR1020100045058
申请日：2010-05-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K31/7105 , C07K14/47
CPC classification number: A61K31/7105 , A61K48/005 , C07K14/4703 , A61K2121/00
Abstract: PURPOSE: A composition containing PIAS3 for preventing or treating cancer or immune diseases is provided to suppress the differentiation of cytotoxic Th17 cell. CONSTITUTION: A composition for preventing or treating cancer or immune diseases contains PIAS3 gene or protein of the gene as an active ingredient. PIAS3 reduces or suppresses the differentiation of undifferentiated T cells into Th17 cells. The immune diseases are autoimmune disease, inflammatory disease, or transplantation rejection. A composition for suppressing immunity contains the PIAS3 gene or protein thereof as an active ingredient.
Abstract translation: 目的：提供含有预防或治疗癌症或免疫疾病的PIAS3的组合物，以抑制细胞毒Th17细胞的分化。 构成：用于预防或治疗癌症或免疫疾病的组合物含有该基因的PIAS3基因或蛋白质作为活性成分。 PIAS3可降低或抑制未分化T细胞分化为Th17细胞。 免疫疾病是自身免疫性疾病，炎性疾病或移植排斥反应。 用于抑制免疫的组合物含有PIAS3基因或其蛋白质作为活性成分。
-
公开(公告)号：KR1020110121086A
公开(公告)日：2011-11-07
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
CPC classification number: A01K67/027 , A01K2207/25 , A01K2227/105 , A01K2267/03
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
Abstract translation: 目的：提供关节炎小鼠动物模型及其制造方法，以更严重地关注关节炎的症状。 构成：关节炎小鼠动物模型的制造方法包括：通过向小鼠喂食高热量饲料来诱导肥胖的步骤; 以及通过在小鼠中服用胶原来引起关节炎的步骤。 在胶原蛋白传代步骤中，首先接种胶原，将小鼠育种一段指定的时间，然后接种胶原蛋白。 在第一次接种中，施用胶原蛋白和完全弗氏佐剂的混合溶液。 在第二次接种中，施用胶原蛋白和不完全弗氏佐剂的混合溶液。
-
100.发明授权
公开(公告)号：KR101044433B1
公开(公告)日：2011-06-27
申请号：KR1020080087109
申请日：2008-09-04
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물의 개선된 제조방법을 제공한다. 또한, 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 류마티스 관절염
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.034 seconds)
